PolyPid (PYPD) Accounts Payables (2019 - 2026)
PolyPid (PYPD) posted Accounts Payables of $1.5 million for Q1 2026, down 46.25% sequentially from $2.9 million in Q4 2025, and down 23.86% YoY from $2.0 million in Q1 2025.
PolyPid (PYPD) Accounts Payables (2019 - 2026) Analysis & Trends
PolyPid has reported Accounts Payables for 8 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Accounts Payables fell 23.86% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 23.86% YoY) and the FY2025 annual result came in at $2.9 million, up 18.56% from the prior year.
- Accounts Payables eased to $1.5 million in Q1 2026 per PYPD's latest filing, from $2.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $3.2 million in Q1 2022 and troughed at $529000.0 in Q3 2023.
- A 5-year average of $1.7 million and a median of $1.5 million in 2026 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables plunged 72.41% in 2022, then surged 212.05% in 2024.
- Over 5 years, Accounts Payables stood at $1.1 million in 2022, then plunged by 32.34% to $772000.0 in 2023, then soared by 212.05% to $2.4 million in 2024, then increased by 18.56% to $2.9 million in 2025, then sank by 46.25% to $1.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.5 million, $2.9 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | 2.57 Mn |
| Mar 31, 2025 | 2.02 Mn |
| Dec 31, 2024 | 2.41 Mn |
| Sep 30, 2024 | 1.64 Mn |
| Jun 30, 2024 | 992,000.00 |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 772,000.00 |
| Sep 30, 2023 | 529,000.00 |
| Jun 30, 2023 | 903,000.00 |
| Mar 31, 2023 | 1.08 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1.03 Mn |
| Jun 30, 2022 | 2.43 Mn |
| Mar 31, 2022 | 3.21 Mn |
| Dec 31, 2021 | 4.14 Mn |
| Sep 30, 2021 | 1.66 Mn |